Vantage logo

Arrowhead delivers in the lung

Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.

Vantage logo

Checking out Checkpoint

Checkpoint Therapeutics’ cosibelimab could become the ninth PD-(L)1 drug to reach the US market, but who will be around to launch it?

Vantage logo

Sofinnova goes digital

The promise of fast timelines and early revenues lure a new investor into digital medicine.